Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
boston blog main
boston top stories
drugs
3
×
inotersen
3
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
patisiran
san diego blog main
san diego top stories
tafamidis
alnylam pharmaceuticals
boston
clinical trials
fda
hereditary transthyretin amyloidosis
onpattro
pfizer
anylam pharmaceuticals
barry greene
biotech
boston university
cardiomyopathy
dan ollendorf
european medicines agency
harvard pilgrim health care
institute for clinical and economic review
john berk
mary o'donnell
neuropathy
new york
regeneron pharmaceuticals
rna interference
san francisco blog main
san francisco top stories
tegsedi
the amyloidosis foundation
What
alnylam
fda
ago
drug
medicine
patients
rna
uses
akcea
amyloidosis
approve
approved
approves
attr
available
awaits
battle
biological
cells
crossed
debilitating
decades
decision
discovered
disease
ema
employ
europe
fingers
follows
friday
gene
genetic
harmful
historic
hits
interference
make
medicines
method
Language
Current search:
inotersen
×
drugs
×
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision